EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice

L DeTolla, R Sanchez, E Khan, B Tyler, M Guarnieri

Journal of Veterinary Medicine · 2014

DOI: 10.1155/2014/365673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Medicine, 2014. Verfasst von L DeTolla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology, Medicine, Epidemiology and Public Health and the Program of Comparative Medicine, School of Medicine, University of Marylan…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: The Maryland Biotechnology Center Biotechnology Development Awards, Maryland Industrial Partnerships, Animalgesic Labs.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subcutaneous drug implants are convenient systems for the long-term delivery of drugs in animals. Lipid carriers are logical tools because they generally allow for higher doses and low toxicity. The present study used an US Food and Drug Administration Target Animal Safety test system to evaluate the safety of a subcutaneous implant of a cholesterol-triglyceride-buprenorphine powder in 120 BALB/c mice. Mice were evaluated in 4- and 12-day trials with 1- and 5-fold doses of the intended 3 mg/kg dose of drug. One male mouse treated with three 3 mg/kg doses and surgery on days 0, 4, and 8 died on day 9. The cause of death was not determined. In the surviving 119 mice there was no evidence of skin reaction at the site of the implant. Compared to control animals treated with saline, weight measurements, clinical pathology, histopathology, and clinical observations were unremarkable. These results demonstrate that the lipid carrier is substantially safe. Cholesterol-triglyceride-drug powders may provide a valuable research tool for studies of analgesic and inflammatory drug implants in veterinary medicine.

Autor:innen und Institutionen

  • Departments of Pathology, Medicine, Epidemiology and Public Health and the Program of Comparative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA.
  • Program of Comparative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA.
  • Johns Hopkins School of Medicine Department of Neurological Surgery, 1550 Orleans Street CRB-264, Baltimore, MD 21231, USA.

Förderung

  • The Maryland Biotechnology Center Biotechnology Development Awards
  • Maryland Industrial Partnerships
  • Animalgesic Labs

Zitieren

APA

DeTolla, L., Sanchez, R., Khan, E., Tyler, B., & Guarnieri, M. (2014). Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. Journal of Veterinary Medicine. https://doi.org/10.1155/2014/365673

Vancouver

DeTolla L, Sanchez R, Khan E, Tyler B, Guarnieri M. Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice. Journal of Veterinary Medicine. 2014. doi:10.1155/2014/365673

BibTeX
@article{DeTolla2014,
  author = {DeTolla, L and Sanchez, R and Khan, E and Tyler, B and Guarnieri, M},
  title = {Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice},
  journal = {Journal of Veterinary Medicine},
  year = {2014},
  doi = {10.1155/2014/365673}
}
Kostenlos starten →